ACADIA (ACAD) Said ACP-104 Fails In Trials
More News related to ACAD
- ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility
- Analyst Reports for Electronic Arts Inc., Teva Pharmaceutical Industries Limited, ACADIA Pharmaceuticals Inc., and Sport Supply Group Inc.
- ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008
- JMP Downgrades ACADIA (ACAD) to Market Perform
- Piper Jaffray Downgrades ACADIA Pharma (ACAD) to Neutral
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most common adverse events in the treatment arms relative to placebo were increased salivation, tachycardia, and dyspepsia, which were noted to be dose-related. There was no clinically significant decrease in neutrophil counts in the study drug arms.
The company said, "we currently do not anticipate conducting further studies with ACP-104."
Related Categories
FDAHot List
Stocks Mentioned
+0.42Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
